keyword
https://read.qxmd.com/read/38614283/postoperative-radiotherapy-results-in-192-epithelial-thymic-tumours-patients-with-10%C3%A2-years-of-follow-up
#21
JOURNAL ARTICLE
Hugo Lopez, Angela Botticella, Farid Belkhir, Benjamin Besse, Elie Fadel, Olaf Mercier, Antonin Levy, Cécile Le Péchoux
PURPOSE: To assess the prognostic factors and patterns of failure of patients consecutively treated with surgery and postoperative radiation therapy (PORT) for thymic epithelial tumours (TET). PATIENTS AND METHODS: Data from 192 TET patients who were operated and received PORT at a single centre from 1990 to 2019 was retrospectively analysed. RESULTS: Most patients had thymoma (77 %, B247%), were classified Masaoka-Koga stage III (35 %) or IV (32 %) and had a R0 (75 %) resection...
April 11, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38613843/utility-of-clinical-and-mr-imaging-parameters-for-prediction-and-monitoring-of-response-to-capecitabine-and-temozolomide-captem-therapy-in-patients-with-liver-metastases-of-neuroendocrine-tumors
#22
JOURNAL ARTICLE
Maria Ingenerf, Christoph Auernhammer, Roberto Lorbeer, Michael Winkelmann, Shiwa Mansournia, Nabeel Mansour, Nina Hesse, Kathrin Heinrich, Jens Ricke, Frank Berger, Christine Schmid-Tannwald
BACKGROUND: This study explores the predictive and monitoring capabilities of clinical and multiparametric MR parameters in assessing capecitabine and temozolomide (CAPTEM) therapy response in patients with neuroendocrine tumors (NET). PATIENTS AND METHODS: This retrospective study (n = 44) assessed CAPTEM therapy response in neuroendocrine liver metastases (NELM) patients. Among 33 monitored patients, as a subgroup of the overall study cohort, pretherapeutic and follow-up MRI data (size, apparent diffusion coefficient [ADC] values, and signal intensities), along with clinical parameters (chromogranin A [CgA] and Ki-67%), were analyzed...
April 14, 2024: Radiology and Oncology
https://read.qxmd.com/read/38611027/effects-of-peptide-receptor-radiotherapy-in-patients-with-advanced-paraganglioma-and-pheochromocytoma-a-nation-wide-cohort-study
#23
JOURNAL ARTICLE
Linda Skibsted Kornerup, Mikkel Andreassen, Ulrich Knigge, Anne Kirstine Arveschoug, Per Løgstup Poulsen, Andreas Kjær, Peter Sandor Oturai, Henning Grønbæk, Gitte Dam
INTRODUCTION: Pheochromocytomas and paragangliomas are rare neuroendocrine tumours that originate from chromaffin cells within the adrenal medulla or extra-adrenal sympathetic ganglia. Management of disseminated or metastatic pheochromocytomas and paragangliomas continues to pose challenges and relies on limited evidence. METHOD: In this study, we report retrospective data on median overall survival (OS) and median progression-free survival (PFS) for all Danish patients treated with peptide receptor radionuclide therapy (PRRT) with 177 Lu-Dotatate or 90 Y-Dotatate over the past 15 years...
March 29, 2024: Cancers
https://read.qxmd.com/read/38610988/autoimmune-atrophic-gastritis-a-clinical-review
#24
REVIEW
Chiara Castellana, Leonardo Henry Eusebi, Elton Dajti, Veronica Iascone, Amanda Vestito, Pietro Fusaroli, Lorenzo Fuccio, Antonietta D'Errico, Rocco Maurizio Zagari
Autoimmune atrophic gastritis (AAG) is a chronic condition characterized by the presence of atrophy in the oxyntic mucosa due to anti-parietal cell antibodies. This review provides a comprehensive and up-to-date overview of autoimmune atrophic gastritis, reporting recent evidence on epidemiology, pathogenesis, diagnosis, clinical presentation, risk of malignancies, and management. The prevalence of AAG has been estimated at between 0.3% and 2.7% in the general population. The diagnosis of AAG is based on a combination of the serologic profile and the histological examination of gastric biopsies...
March 28, 2024: Cancers
https://read.qxmd.com/read/38609739/corrigendum-to-sex-differences-on-multikinase-inhibitors-toxicity-in-patients-with-advanced-gastroenteropancreatic-neuroendocrine-tumours-%C3%A2-eur%C3%A2-j%C3%A2-cancer-188%C3%A2-2023-39-48
#25
Jorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, Eric Raymond, Philippe Ruszniewski, Matthew H Kulke, Enrique Grande, Rocío García Carbonero, Daniel Castellano, Ramón Salazar, Toni Ibrahim, Alex Teule, Vicente Alonso, Nicola Fazio, Juan W Valle, Salvatore Tafuto, Ana Carmona, Victor Navarro, Jaume Capdevila
No abstract text is available yet for this article.
April 11, 2024: European Journal of Cancer
https://read.qxmd.com/read/38605054/gastric-neuroendocrine-neoplasms
#26
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 11, 2024: Nature Reviews. Disease Primers
https://read.qxmd.com/read/38605021/gastric-neuroendocrine-neoplasms
#27
REVIEW
Giuseppe Lamberti, Francesco Panzuto, Marianne Pavel, Dermot O'Toole, Valentina Ambrosini, Massimo Falconi, Rocio Garcia-Carbonero, Rachel P Riechelmann, Guido Rindi, Davide Campana
Gastric neuroendocrine neoplasms (gNENs) display peculiar site-specific features among all NENs. Their incidence and prevalence have been rising in the past few decades. gNENs comprise gastric neuroendocrine carcinomas (gNECs) and gastric neuroendocrine tumours (gNETs), the latter further classified into three types. Type I anatype II gNETs are gastrin-dependent and develop in chronic atrophic gastritis and as part of Zollinger-Ellison syndrome within a multiple endocrine neoplasia type 1 syndrome (MEN1), respectively...
April 11, 2024: Nature Reviews. Disease Primers
https://read.qxmd.com/read/38598035/advances-in-radionuclide-therapies-for-patients-with-neuro-endocrine-tumors
#28
REVIEW
Denise S Hoogenkamp, Linda J de Wit-van der Veen, Daphne M V Huizing, Margot E T Tesselaar, Rachel S van Leeuwaarde, Marcel P M Stokkel, Marnix G E H Lam, Arthur J A T Braat
PURPOSE OF REVIEW: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments. RECENT FINDINGS: Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i...
April 10, 2024: Current Oncology Reports
https://read.qxmd.com/read/38595826/von-hipple-lindau-syndrome-with-family-history-a-case-report-and-seventeen-years-follow-up-study
#29
XueMei Fan, Shuai Wang, Tianwen Chen, Wei Hu, Hui Yang
BACKGROUND: Von-Hipple Lindau syndrome is an uncommon autosomal dominant disorder. 17 years ago we diagnosed a young woman with VHL syndrome validated by Sanger sequencing, her family members were genetically tested as well, and 187 healthy people were randomly selected for VHL genetic testing as controls. We analyze the clinical and genetic characteristics of VHL syndrome in a Chinese lineage and with 17-year follow-up. CASE PRESENTATION: A woman was finally diagnosed with VHL syndrome due to the detection of a missense mutation c...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38592317/endoscopic-resection-for-duodenal-neuroendocrine-neoplasms-between-10-and-20-mm-a-systematic-review-and-meta-analysis
#30
REVIEW
Roberta Elisa Rossi, Benedetta Masoni, Sara Massironi, Giacomo Marcozzi, Gianluca Franchellucci, Angelo Zullo, Antonio Facciorusso, Silvia Carrara, Nadim Mahmud, Giulia Migliorisi, Silvia Ferretti, Roberta Maselli, Cesare Hassan, Alessandro Repici
Background. The optimal management of duodenal neuroendocrine neoplasms (dNENs) sized 10-20 mm remains controversial and although endoscopic resection is increasingly performed instead of surgery, the therapeutic approach in this setting is not fully standardized. We performed a systematic review of the literature and a meta-analysis to clarify the outcomes of endoscopic resection for 10-20 mm dNENs in terms of efficacy (i.e., recurrence rate) and safety. Methods. A computerized literature search was performed using relevant keywords to identify pertinent articles published until January 2023...
March 2, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38591867/phase-ii-study-of-osimertinib-in-patients-with-epidermal-growth-factor-receptor-mutations-results-from-the-nci-match-ecog-acrin-eay131-trial-subprotocol-e
#31
JOURNAL ARTICLE
Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, Yoshie Umemura, James V Tricoli, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty
PURPOSE: The National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the basis of next-generation sequencing results. Subprotocol E evaluated osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with EGFR mutations. METHODS: Eligible patients had EGFR mutations (T790M or rare activating) and received osimertinib 80 mg once daily...
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38590270/prevalence-of-metastases-outside-the-liver-and-abdominal-lymph-nodes-on-68-ga-dotatoc-pet-ct-in-patients-with-small-intestinal-and-pancreatic-neuroendocrine-tumours
#32
REVIEW
Maria Wedin, Eva Tiensuu Janson, Göran Wallin, Anders Sundin, Kosmas Daskalakis
Metastases outside the liver and abdominal/retroperitoneal lymph nodes are nowadays detected frequently in patients with neuroendocrine tumours (NETs), owing to the high sensitivity of positron emission tomography (PET) with Gallium-68-DOTA-somatostatin analogues (68 Ga-SSA) and concomitant diagnostic computed tomography (CT). Our aim was to determine the prevalence of extra-abdominal metastases on 68 Ga-DOTATOC-PET/CT in a cohort of patients with small intestinal (Si-NET) and pancreatic NET (Pan-NET), as well as that of pancreatic metastasis in patients with Si-NET...
April 9, 2024: Journal of Neuroendocrinology
https://read.qxmd.com/read/38588886/gastric-carcinoma-in-autoimmune-gastritis-a-histopathologic-and-molecular-study
#33
JOURNAL ARTICLE
Valentina Angerilli, Alessandro Vanoli, Giulia Celin, Carlotta Ceccon, Jessica Gasparello, Marianna Sabbadin, Giuseppe De Lisi, Michele Paudice, Marco Vincenzo Lenti, Laura Rovedatti, Antonio Di Sabatino, Francesca Bazzocchi, Sara Lonardi, Edoardo Savarino, Claudio Luchini, Paola Parente, Federica Grillo, Luca Mastracci, Matteo Fassan
Patients with autoimmune gastritis (AIG) have a 13-fold risk of developing type-1 neuroendocrine tumors, whereas the risk for gastric adenocarcinoma is still uncertain. Here we describe the clinicopathological and molecular features of a series of gastric carcinomas (GC) arising in the context of AIG. A total of 26 AIG-associated GC specimens were collected from four Italian Institutions. Immunohistochemistry for MUC1, MUC2, MUC5AC, MUC6, CDX2, HER2, PD-L1, CLDN18, Mismatch Repair (MMR) proteins, and p53 and EBER in situ hybridization were performed...
April 6, 2024: Modern Pathology
https://read.qxmd.com/read/38586554/fate-of-small-remnant-pancreatic-tail-in-splenic-hilum-after-laparoscopic-spleen-preserving-distal-pancreatectomy-a-retrospective-study
#34
JOURNAL ARTICLE
Okjoo Lee, So Kyung Yoon, So Jeong Yoon, Hongbeom Kim, In Woong Han, Jin Seok Heo, Sang Hyun Shin
PURPOSE: When performing laparoscopic spleen-preserving distal pancreatectomy (LSPDP), sometimes, anatomically challenging patients are encountered, where the pancreatic tail is deep in the splenic hilum. The purpose of this study was to discuss the experience with the surgical technique of leaving the deep pancreatic tail of the splenic hilum in these patients. METHODS: Eleven patients who underwent LSPDP with remnant pancreatic tails between November 2019 and August 2021 at Samsung Medical Center in Seoul, Korea were included in the study...
April 2024: Annals of Surgical Treatment and Research
https://read.qxmd.com/read/38584068/etv6-ntrk2-fusion-in-a-patient-with-metastatic-pulmonary-atypical-carcinoid-successfully-treated-with-entrectinib-a-case-report-and-review-of-the-literature
#35
REVIEW
Wusheng Zhang, Sen Tian, Xiang Li, Yilin Chen, Xinyu Wang, Yunshuo Zhang, Lihui Lv, Yonghua Li, Hui Shi, Chong Bai
Pulmonary atypical carcinoid (AC) is an extremely rare neuroendocrine tumor. The neurotrophic tropomyosin receptor kinase (NTRK) fusions are reported in only 0.5% of nonsmall cell lung cancer, and are more rare in AC with only one previously reported case. Currently, there is little established evidence on the optimal therapeutic strategies and prognosis for advanced cases. We present a female patient with metastatic AC after complete resection. Due to low expression of somatostatin receptor in this case, somatostatin analogs and peptide receptor radionuclide therapy were not available...
March 19, 2024: Clinical Lung Cancer
https://read.qxmd.com/read/38582207/-fifteen-years-of-experience-with-surgical-management-of-bilateral-non-familial-carotid-body-tumors
#36
JOURNAL ARTICLE
Luis O Bobadilla-Rosado, Javier E Anaya-Ayala, Aliberth Bonilla, Santiago Mier Y Teran-Ellis, Montserrat Miranda-Ramirez, Hugo Laparra-Escareno, Nina Mendez-Dominguez, Carlos A Hinojosa
OBJECTIVE: Bilateral carotid body tumors (CBT) are infrequent neuroendocrine neoplasms. We conducted this work to describe our experience in the surgical treatment of bilateral CBT and to analyse our results METHODS: A retrospective, observational study. We analysed the totality of bilateral CBT resections that had been performed in our institution from January 2008 to September 2023. Data was obtained from medical records and anonymized, ethics approval was obtained from our institution committee...
April 4, 2024: Annals of Vascular Surgery
https://read.qxmd.com/read/38581593/adrenal-tumors-in-patients-with-neuroendocrine-neoplasms
#37
JOURNAL ARTICLE
Henrik Falhammar, Adam Stenman, C Christofer Juhlin, Anna Kistner
PURPOSE: To study the prevalence of primary adrenal tumors and adrenal metastases in patients with neuroendocrine neoplasms (NENs) and describe these in detail. NENs can be further divided into neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC). METHODS: A review of medical files was conducted for all patients who underwent a 68 Gallium-DOTATOC-PET/CT during 2010-2023 or adrenalectomy during 1999-2023 at the Karolinska University Hospital. RESULTS: In total, 68 Gallium-DOTATOC-PET/CT was performed on 1750 individuals with NEN, among whom 12 (0...
April 6, 2024: Endocrine
https://read.qxmd.com/read/38581469/radionuclide-theranostics-in-neuroendocrine-neoplasms-an-update
#38
REVIEW
Martina Di Franco, Lucia Zanoni, Emilia Fortunati, Stefano Fanti, Valentina Ambrosini
PURPOSE OF REVIEW: This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT). RECENT FINDINGS: Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET...
April 6, 2024: Current Oncology Reports
https://read.qxmd.com/read/38581426/ewing-sarcoma-of-the-mandible-a-rare-case-report-and-literature-review
#39
JOURNAL ARTICLE
Özgecan Gündoğar, Neslihan Komut, Sibel Bektaş, Fatih Tetik, Neşe Uçar
Ewing sarcoma (ES) usually arises from long bones and affects the head and neck region in only 1%-4% of cases. We reported clinical, radiographic, cytomorphologic, and histomorphologic findings of the ES in the mandible, because of its rarity and radiologically misinterpreted as a parotid gland tumor. A 26-year-old male patient presented with a history of painfull cheek swelling. On magnetic resonance imaging, a mass measuring 50 × 48 × 45 mm was found eroding mandible and pushing back the parotid gland...
April 6, 2024: Diagnostic Cytopathology
https://read.qxmd.com/read/38580271/cre24-051-rare-case-of-a-paraneoplastic-cerebellar-ataxia-secondary-to-a-retroperitoneal-neuroendocrine-tumor-of-unknown-origin
#40
Khushboo Lakhatariya, Fehmida Laxmidhar, Mrunal Patel
No abstract text is available yet for this article.
April 5, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
keyword
keyword
85606
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.